Sometimes, buying low can work as a balance, almost a strange sort of diversification.
Besides Tesla, Twitter and Biogen make good candidates.
These are the biggest errors that I've made over the years.
Go ahead and sell Valeant on the news, if you want. But history has a different lesson.
If buyers don't appear around $78 then a deeper correction is likely.
Despite this year-long profit recession, the U.S. is still the best game in town.
BMY is unlikely to stay in the low $60s for long.
The failed trial is among the biggest single blows by a major pharma player.
A lot of price damage has been inflicted on this stock.
There is a case for a low already being in place.

Columnist Conversations

Raytheon is building on Tuesday's impressive breakout.  The defense name is up over 1.25% ahead of tonigh...
Merck had a nice earnings beat on Tuesday which was accompanied by an earlier than expected FDA approval on Ke...
For years Apple was accused of under promise, over deliver --- UPOD as Jim Cramer likes to call it.  Whil...
Market down across the board, as less than optimistic outlook from Apple (AAPL) dampens investor enthusiasm in...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.